Table 2 Characteristics of the AML patients by high and low expression levels of RUNX1
| Â | RUNX1 over-expressors (n = 46) | RUNX1 low-expressors (n = 45) | p value |
|---|---|---|---|
Age (years) | 36.0 ± 10.9 | 34.9 ± 12.3 | 0.434 |
Sex | |||
 Male | 30 (60.0%) | 20 (40.0%) | 0.046 |
 Female | 16 (39.0%) | 25 (61.0%) |  |
TLC (× 103/mm3) | 50.7(1.0–440.0) | 25.1 (1.7–281.7) | 0.191 |
Hb (gm/dL) | 7.8 ± 1.8 | 8.3 ± 1.7 | 0.267 |
PLT (× 103/mm3) | 32.0 (6.0–208.0) | 35.0 (5.0–297.0) | 0.923 |
PB blasts (%) | 59.0 (10.0–95.0) | 48.5 (0.0–98.0) | 0.229 |
BM blasts (%) | 72.0 (30.0–97.0) | 70.0 (0.0–95.0) | 0.282 |
FAB1 | |||
 M1, M2 | 27 (55.1%) | 22 (44.9%) | 0.348 |
 M4, M5, M7 | 19 (45.2%) | 23 (54.8%) |  |
FLT3 | |||
 Mutant | 11 (78.6%) | 3 (21.4%) | 0.023 |
 Wild | 35 (45.5%) | 42 (54.5%) |  |
NPM | |||
 Mutant | 5 (55.6%) | 4 (44.4%) | 1.000 |
 Wild | 7 (50.0%) | 7 (50.0%) |  |
Molecular markers | |||
 −ve | 39 (50.6%) | 38 (49.4%) | 0.964 |
 +ve | 7 (50.0%) | 7 (50.0%) |  |
Genetics | |||
 Abnormal | 11 (45.8%) | 13 (54.2%) | 0.590 |
 Normal | 35 (52.2%) | 32 (47.8%) |  |
Genetic risk | |||
 Favorable | 8 (44.4%) | 10 (55.6%) | 0.363 |
 Intermediate | 24 (47.1%) | 27 (52.9%) |  |
 Adverse | 14 (63.6%) | 8 (36.4%) |  |